Company: BLRX
Filing Date: 2025-01-07
Form Type: 6-K
Source: 0001178913-25-000047
Chunk: 3

Company: BioLineRx Ltd.
Filing Date: 2025-01-07
Form: 6-K
Chunk 3
---
 of the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward looking statements are based upon the Company’s present intent, beliefs or expectations, but forward looking statements are not guaranteed to occur and may not occur for various reasons, including some reasons which are beyond the Company’s control. For example, this Report states that the Offering is expected to close on or about January 7, 2025. In fact, the closing of the Offering is subject to various conditions and contingencies as are customary in securities purchase agreements in the United States. If these conditions are not satisfied or the specified contingencies do not occur, this Offering may not close. For this reason, among others, you should not place undue reliance upon the Company’s forward looking statements. Except as required by law, the Company undertakes no obligation to revise or update any forward looking statements in order to reflect any event or circumstance that may arise after the date of this Report on Form 6-K. Attached hereto are the following exhibits:

| Exhibit No. |     | Description                                                                |
| 5.1         |     | Opinion of FISCHER (FBC & Co.)                                             |
| 5.2         |     | Opinion of Greenberg Traurig, P.A.                                         |
| 10.1        |     | Form of Securities Purchase Agreement dated as of January 6, 2025, between 
 BioLineRx Ltd. and the investors signatory thereto                         |
| 10.2        |     | Form of Pre-Funded Warrant                                                 |
| 10.3        |     | Form of Ordinary Warrant                                                   |
| 23.1        |     | Consent of FISCHER (FBC & Co.) (contained in Exhibit 5.1)                  |
| 23.2        |     | Consent of Greenberg Traurig, P.A. (contained in Exhibit 5.2)              |

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| BioLineRx Ltd. |                         |
| By:            | /s/ Philip Serlin       |
|                | Philip Serlin           |
|                | Chief Executive Officer |

Dated: January 7, 2025